BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28285685)

  • 21. Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment.
    Chin TM; Quinlan MP; Singh A; Sequist LV; Lynch TJ; Haber DA; Sharma SV; Settleman J
    Clin Cancer Res; 2008 Nov; 14(21):6867-76. PubMed ID: 18980981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.
    Martin P; Stewart E; Pham NA; Mascaux C; Panchal D; Li M; Kim L; Sakashita S; Wang D; Sykes J; Friess T; Shepherd FA; Liu G; Tsao MS
    Clin Lung Cancer; 2016 Sep; 17(5):375-383.e2. PubMed ID: 26926157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib.
    Yonesaka K; Hirotani K; Kawakami H; Takeda M; Kaneda H; Sakai K; Okamoto I; Nishio K; Jänne PA; Nakagawa K
    Oncogene; 2016 Feb; 35(7):878-86. PubMed ID: 25961915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation.
    Kim N; Cho A; Watanabe H; Choi YL; Aziz M; Kassner M; Joung JG; Park AK; Francis JM; Bae JS; Ahn SM; Kim KM; Park JO; Park WY; Ahn MJ; Park K; Koo J; Yin HH; Cho J
    Oncotarget; 2016 Mar; 7(12):13797-809. PubMed ID: 26883194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experience with erlotinib in the treatment of non-small cell lung cancer.
    Landi L; Cappuzzo F
    Ther Adv Respir Dis; 2015 Aug; 9(4):146-63. PubMed ID: 26063687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
    Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
    J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
    Leone A; Roca MS; Ciardiello C; Terranova-Barberio M; Vitagliano C; Ciliberto G; Mancini R; Di Gennaro E; Bruzzese F; Budillon A
    Free Radic Biol Med; 2015 Dec; 89():287-99. PubMed ID: 26409771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.
    Hwang KE; Kwon SJ; Kim YS; Park DS; Kim BR; Yoon KH; Jeong ET; Kim HR
    Exp Cell Res; 2014 May; 323(2):288-96. PubMed ID: 24631288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
    Botting GM; Rastogi I; Chhabra G; Nlend M; Puri N
    PLoS One; 2015; 10(8):e0136155. PubMed ID: 26301867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
    Chen Q; Quan Q; Ding L; Hong X; Zhou N; Liang Y; Wu H
    Oncotarget; 2015 Sep; 6(28):24904-11. PubMed ID: 26172562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.
    Zhao R; Zhou S; Xia B; Zhang CY; Hai P; Zhe H; Wang YY
    BMC Cancer; 2016 Jul; 16():491. PubMed ID: 27431492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
    Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS
    Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
    PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evodiamine induces apoptosis and enhances apoptotic effects of erlotinib in wild-type EGFR NSCLC cells via S6K1-mediated Mcl-1 inhibition.
    Li YL; Pan YN; Wu WJ; Mao SY; Sun J; Zhao YM; Dong JY; Zhang DY; Pan JP; Zhang C; Lin NM
    Med Oncol; 2016 Feb; 33(2):16. PubMed ID: 26757927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.
    Halmos B; Pennell NA; Fu P; Saad S; Gadgeel S; Otterson GA; Mekhail T; Snell M; Kuebler JP; Sharma N; Dowlati A
    Oncologist; 2015 Nov; 20(11):1298-303. PubMed ID: 26306902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
    Formisano L; D'Amato V; Servetto A; Brillante S; Raimondo L; Di Mauro C; Marciano R; Orsini RC; Cosconati S; Randazzo A; Parsons SJ; Montuori N; Veneziani BM; De Placido S; Rosa R; Bianco R
    Oncotarget; 2015 Sep; 6(28):26090-103. PubMed ID: 26325669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib.
    de La Motte Rouge T; Galluzzi L; Olaussen KA; Zermati Y; Tasdemir E; Robert T; Ripoche H; Lazar V; Dessen P; Harper F; Pierron G; Pinna G; Araujo N; Harel-Belan A; Armand JP; Wong TW; Soria JC; Kroemer G
    Cancer Res; 2007 Jul; 67(13):6253-62. PubMed ID: 17616683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autophagy inhibition facilitates erlotinib cytotoxicity in lung cancer cells through modulation of endoplasmic reticulum stress.
    Wang Z; Du T; Dong X; Li Z; Wu G; Zhang R
    Int J Oncol; 2016 Jun; 48(6):2558-66. PubMed ID: 27035631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.